Naturally occurring CD4 + CD25 + Treg cells (nTregs) can be exploited to establish an immunologic tolerance to non-self-antigens. The in vivo administration of a single superagonistic CD28-specific monoclonal antibody (supCD28mAb) to naive rat preferentially expanded the nTregs, which induced a potent inhibition of lethality of the graft-versus-host (GvH) diseases. The appearance of increased Foxp3 molecules was accompanied with a polarization towards a Th2 cytokine profile with a decreased production of IFN-γ and increased production of IL-4 and IL-10 in the serum of the antibody-treated rat. The peripheral Foxp3 nTregs are decreased in acute GvHD, while supCD28mAb administration showed that nTregs were preferentially proliferating in vivo, thus resulting in the significant prevention of the GvH disease. Furthermore, antigen-specific nTregs could suppress conventional T-cell proliferation stimulated with alloantigen in vitro. Taken together, our findings demonstrate that the potent regulatory functions of the Tregs for the treatment of GvHD are antigen specific. These data also provide evidence that GvHD is associated with decrease of Tregs in the periphery of the host. The determination of the Foxp3 Tregs can be a helpful tool to discriminate GvHD severity and lethality after allogeneic stem cell transplantation.
INTRODUCTION
(10, 16, 17) . For example, the elimination of nTregs leads to the spontaneous development of various autoimmune diseases in normal animals and provokes effective tumor Naturally occurring CD4 + CD25 + Treg cells (nTregs) function as key regulatory effectors in mice and have immunity in otherwise nonresponding animals (8, 15, 18, 20, 21) . The elimination also enhances immune responses provided important information regarding a specific cellular population that performs immune regulation to non-self-antigens, including the allogeneic transplantation antigens (10). A crucial area for future study is through the suppression of self-responses (1) . A thymectomy on neonatal day 3 that resulted in multiorgan auto-the identification of the cytokine drugs or costimulatory molecules that reverse energy and enhance growth, immune disease (gastritis, thyroiditis, or insulitis) was associated with the loss of this nTreg population while preserving the suppressor function of the nTregs population. The optimal stimulus for the expansion of (9, 14, 20) . The outcome of the alloimmune response following transplantation is, in part, dependent on the bal-the nTregs in vitro is the combination of TCR triggering and high concentrations of IL-2. Once the specific anti-ance between the stimulatory and inhibitory signals that accompany TCR engagement by an alloantigen (13) , gens that are recognized by nTregs in organ-specific autoimmunity have been defined, the antigen can then be and there is little doubt that nTregs is one of the inhibitor cells that suppresses excessive immune responses administered in combination with IL-2, in order to expand the nTreg cell population that is specific for the and maintains immune homeostasis (16) .
Accumulating evidence indicates that nTregs play a target organ. The administration of the target antigen on iDCs together with IL-2 may be a particularly effective crucial role in the maintenance of immunologic selftolerance and the negative control of immune responses method for the expansion of nTregs suppressors in vivo.
Our previous studies (2, 7, 8) showed that the in vivo week-old (Lewis × DA) F1 or DA tolerant of (Lewis × DA) F1 rats. Antibodies (supCD28mAb, JJ316) were application of the unique supCD28mAb to Lewis rat caused a preferential expansion of Foxp3-expressing administered to the host rat via tail veins at the various points (day −3, 0, 3, 7, and 10 after T-cell infusion). The nTregs over conventional T cells, and maintained not only their phenotype but also their potent regulatory rats were weighed on alternate days during the active phase of the GvHD. Animals undergoing typical GvHD functions against T-cell proliferation via the mitogens, antibodies, and allostimulation in vitro. In addition, the showed rapid weight loss and commonly described signs of the disease, including ruffled fur, reddening of the skin, in vivo application also suppressed the alloreactive Tcell response in a model of GvHD and indicated that this a hunched posture, and ultimately death. therapeutic effect was mediated by in vivo expansion of CD4 + CD25 + and CD4 + CD25 − T-Cell Purification nTregs (7,12). Furthermore, using a full MHC-mismatch transplantation model, we found that supCD28mAb
For the isolation of purified CD4 + CD25 + and CD4 + CD25 − T cells, splenocytes were first stained with preferentially expanded nTregs in vivo and recruited to the grafts, thus resulting in significantly prolonged car-FITC-conjugated anti-rat CD8, CD11b/c, and NK1.1 (BD Pharmingen, San Diego, CA) followed by anti-diac and kidney graft survival (7, 8) .
In the present study, the in vivo administration of a FITC MicroBeads (Miltenyi Biotec, K.K. Tokyo, Japan) and anti-rat Kappa MicroBeads (Miltenyi Biotec) and single supCD28mAb to naive rat preferentially expanded nTregs, which in turn induced a potent inhibition then sorted on an AutoMACS system (Miltenyi Biotec).
To isolate CD4 + CD25 + T cells, the negative fraction of of the lethality of GvHD. The peripheral Foxp3 nTregs are decreased in acute GvHD, while supCD28mAb ad-the enriched CD4 + CD8 − cells was stained with biotinylated anti-rat CD25 (BD Pharmingen) followed by anti-ministration showed that nTregs were preferentially proliferated in vivo, and resulted in a significant prevention biotin MicroBeads (Miltenyi Biotec) and sorted on an Auto MACS. The negative fraction, enriched of GvHD. Taken together, our findings demonstrate that the potent regulatory functions of Tregs for the treat-CD4 + CD25 − cells, was labeled with anti-rat CD4 MicroBeads (BD Pharmingen) sorted on an Auto ment GvHD are antigen specific. These data also provide evidence that GvHD is associated with a decrease MACS. The enriched T-cell populations were evaluated by FACScan (Becton Dickinson) and more than 92% of Tregs in the periphery of the host. The determination of the Foxp3 Tregs can be a useful tool for discriminat-purity of the CD4 + CD25 + and 95% purity of the CD4 + CD25 − cells population were routinely obtained. ing the severity and lethality of GvHD after an allogeneic stem cell transplantation.
T-Cell Proliferation Assays MATERIALS AND METHODS
CD4 + CD25 + T cells from naive Lewis or DA rat Animals spleens were prepared and mixed (1:1) with Lewis CD4 + CD25 − T cell (1 × 10 5 ) and cultured with DA Adult male Lewis (RT1 l ), DA (RT1 a ), and (Lewis × spleen CD11b/c + cells (APCs, 1 × 10 4 ) in a U-bottom DA) F1 rats were purchased from Shizuoka Laboratory 96-well plate (Iwaki, Tokyo, Japan) at a final volume of Animal Center (Shizuoka, Japan) and used at 4-6 weeks 200 µl/well in a humidified atmosphere at 37°C for 5 of age. The DA tolerant of (Lewis × DA) F1 rats were days. The proliferation of T cells was measured with made by injection of 1 × 10 8 /150 µl (Lewis × DA) F1 cell proliferation ELISA kits (Roche Diagnostics Gmbh, bone morrow cells to the neonatal DA rats (11) . The Penzberg, Germany) (4). Briefly, the cells were labeled animals were maintained under standard conditions and with 5-bromo-2-deoxyuridine (BrdU) solution at 10 µl/ fed rodent food and water according to the laboratory well and incubated for an additional 2 h at 37°C. After animal care principles and the guide for the care and use centrifugation, the supernatant was removed, 200 µl/ of laboratory animals established by our institution.
well of fixation and DNA denaturation (FixDenat) solu-Total Spleen Cell Purification and Assay of Systemic tion was added to the cells, and they were reincubated GvH Reactivity for 30 min at 15-25°C. The cells were cultured for 90 min with anti-BrdU-peroxidase solution and subse-For the preparation of purified spleen cells, naive Lewis rat spleens were harvested and gently ground with quently washed three times. After adding substrate solution at 100 µl/well, the BrdU incorporation was mea-frosted objective slides in PBS. They were filtered through 200-µm nylon mesh for single-cell suspension sured with a chemiluminescence reader (Wallac ARVO TM SX; Perkin Elmer, Inc., Wellesley, MA) and the data preparation and then separated by Lympholyte-Rat (Cedarlane Laboratories, Ontario, Canada). Total spleen sin-was processed using Wallac1420 manager software (Perkin Elmer). gle-cell suspensions (2.5 × 10 8 ) were injected IV into 4-
Flow Cytometric Analysis
2, IL-4, and IL-10 mRNA in comparison to CD4 + CD25 − T cells and to nTreg cells (7,8). In the present study, Host T cells from supCD28mAb-treated or IgGwe investigated the concentration of the cytokines in the treated control (Lewis × DA) F1 rat spleens and periphserum from the Lewis rats that received a supCD28mAb eral blood were collected and suspended in PBS and intreatment at the various time points ( Fig. 1 ). Consistent cubated at 4°C for 30 min with an optimal concentration with the mRNA expression data, we found that the ILof Cy-Chrome-conjugated anti-rat CD4 antibody (OX-2 and IFN-γ production exhibited a high level on day 7 35, BD Pharmingen) in combination with FITC-conjuand day 3, respectively. In addition, IL-10 and IL-4 gated anti-rat CD25 antibody (OX-39, BD Pharmingen) showed significantly high concentrations on both day 3 diluted with PBS containing 1% fetal calf serum. The and day 7, whereas the other kinds of cytokines such as membranes were stained and intracellular staining was IL-6 and TNF-α showed no change (data not shown). then performed using a BD Cytofix/Cytoperm TM Kit (BD Pharmingen). The cells were fixed with 100 µl of supCD28mAb Treatment Suppressed GvH Reactions BD Cytofix/Cytoperm TM (BD Pharmingen) at 4°C for 20
A clinically relevant in vivo model was used to invesmin. The cells were next washed twice with BD Perm/ tigate the role of the supCD28mAb treatment on the allo Wash TM buffer (BD Pharmingen) and then resuspended responses in vivo ( Fig. 2A) . The systemic GvH reactivin 50 ml of the same buffer containing the optimal conity of the supCD28mAb treatment was tested by injectcentration of PE-conjugated anti-Foxp3 antibody (FJKing an antibody via the tail veins, at the various time 16s, eBioscience, San Diego, CA) for permeabilization. points (day −3, 0, 3, 7, and 10 after the spleen cell infu-The cells were gently mixed and incubated for 30 min sion), of the (Lewis × DA) F1 hybrid recipients. As in the dark at 4°C. They were then washed twice with shown in Table 1 and Figure 2B and C, the rats that BD Perm/Wash TM buffer and resuspended in a staining received 2.5 × 10 8 naive Lewis spleen lymphocytes debuffer. Thereafter, the cells were analyzed by flow cyveloped host's weight loss and definite lethality (surtometry (FACScan, Becton Dickinson). The charactervived to 15 ± 1.3 days). The supCD28mAb treatment, ization of the DA tolerant of (Lewis × DA) F1 rat was on day 3 before the spleen cell transfer, did not mediate performed by FCM analysis using a specific antibody GvHD lethality in any of the recipients in comparison (clone I1-69) recognized the Lewis MHC class I molecto the control (60 ± 0.0 days). Furthermore, the supCD2 ular.
8mAb treatment on day 0 significantly inhibited GvHD mortality (39.9 ± 18.0 days) in comparison to the recipi-Cytokine Assay ents that received only the naive spleen cells (p = 0.0001) Serum were collected and quantified by BD Cytome-( Fig. 2B , C). Consistent with these observations, the extric Bead Array rat IL-4, IL-10 Flex Kit (BD Bioscitensive perivascular infiltration of the mononuclear cells ences) or IL-2, IL-4, IL-10, and IFN-γ rat ELISA kit and the tissue damage were observed in the histological (BioSource, Camarillo, CA) according to the manufacstudies of the skin, tongue, lung, and liver from the naturer's protocol.
ive lymphocytes transferred to the host on day 14 (7). In contrast, relatively few infiltrating mononuclear cells Statistical Analysis and almost normal tissue architecture were observed in Student's t-test was used to compare the paired and the supCD28mAb group (data not shown). On the other unpaired variables. A statistical evaluation for graft surhand, there was no protective effect in the supCD28mAb vival was performed using the Kaplan-Meier's test. Valtreatment group on day 7 and day 10. ues of p < 0.05 were considered to be statistically significant. All in vitro experiment data were representative Kinetic Changes of the CD4 + CD25 + T Cells of three independent experiments and expressed as the and Foxp3 + Tregs Population in GvHD Host mean ± SD.
Spleen and Peripheral Blood (PB)
A kinetic analysis of the Foxp3 + cells in the periph-RESULTS eral blood of the GvHD host was conducted (Fig. 3A) .
Cytokine Concentrations in the Serum
The FCM analysis showed a progressive increase of the From supCD28mAb-Treated Rats CD4 + CD25 + T-cell population on day 7 in PB and on day 3 in the spleen, after the transfer of the naive Lewis We showed previously that a single injection of supCD28mAb led to a significant increase in the lymphocytes, accompanied by a decrease of the Foxp3 + cells in CD4 + CD25 + T-cell populations on day 7 in PB CD4 + CD25 + population in the spleen, the peripheral blood, and the lymph nodes, and the expanded and on day 3 in spleen (Fig. 3B ). The population of the CD4 + CD25 + T cells in the total lymphocytes and Foxp3 + CD4 + CD25 + T cells expressed much higher levels of IL- cells in CD4 + CD25 + T cells was maintained at a fixed ive Lewis lymphocytes to DA tolerant of (Lewis × DA) F1 rat leads to host's weight loss and a definite lethality. level in the spleen and the PB of the nontreated control group.
However, there was no protective effect on the group receiving the supCD28mAb treatment on day 3 com-CD4 + CD25 + T-Cell and Foxp3 + Treg Populations pared to the same antibody-treated (Lewis × DA) F1 rat in Host Spleen and PB on Day 14 After group, which did not mediate GvHD lethality in any re-supCD28mAb Treatment cipients (Fig. 2) .
The changes of the CD4 + CD25 + T-cell and Foxp3 + nTregs Can Suppress the T-Cell Proliferation Treg populations in host spleen and PB after supCD28
Antigen Specifically mAb treatment were investigated. An FCM analysis in Figure 4 showed the CD4 + CD25 + T-cell population on
In order to examine the antigen-specific nTregs activity, suppression assays were performed with autologous day 14 in spleen and PB, after the transfer of naive Lewis lymphocytes, increased, accompanied by a de-naive Lewis rat and allogeneic DA rat nTregs to test their suppressive activity using a mixed lymphocyte re-crease of the Foxp3 + cells in the CD4 + CD25 + T-cell populations. In contrast, the population of the CD4 + CD25 + action assay. In agreement with this finding in the in vivo study (Figs. 2 and 5), Lewis nTregs inhibited the T cells in total lymphocyte was maintained at a fixed level and Foxp3 + cells dramatically increased in CD4 + proliferation of naive Lewis CD4 + CD25 − T cells stimulated with allogeneic DA rat APCs, at a ratio of 1:1, CD25 + T cells in supCD28mAb treatment on day 3. Similar to the untreated control group, the CD4 + CD25 + while the nTregs from DA rat had no effect on the suppression of Lewis CD4 + CD25 − T-cell proliferation (Fig. 6) . T cells increased and the Foxp3 + cells decreased in the antibody-treated noneffective group (day 10).
DISCUSSION Prevention of GvHD by supCD28mAb-Expanded
The recent attempts to translate the supCD28mAb-nTregs Was Antigen Specific mediated nTreg stimulation failed because of an unexpected induction of a life-threatening cytokine release Lastly, to clarify whether or not the activity of the supCD28mAb-expanded nTregs was antigen specific, syndrome (19) . The transient polyclonal Tregs activation, regardless of the stimulus used for its induction, we used a neonatal tolerant model to make a unique DA tolerant of (Lewis × DA) F1 rat (Fig. 5A) . Briefly, 1 × still represents an attractive therapeutic option in autoimmunity and in transplantation tolerance. In the present 10 8 /150 µl (Lewis × DA) F1 bone morrow cells were injected into the neonatal DA rats (6,11) and, 4 weeks study we investigated the concentration of the cytokines in the serum from the Lewis rats that were treated with after, the characterization was performed by an FCM analysis using a specific antibody (clone I1-69) that rec-supCD28mAb at various time points. Consistent with our previous data on the mRNA expression (2,7), we ognized the Lewis MHC class I molecules (Fig. 5B ). As shown in Table 2 and Figure 5C , the transfer of the na-found that the IL-2 and IFN-γ production exhibited a high level on day 7 and day 3, respectively. In addition, mediate GvHD lethality in any recipients in comparison to the control. Furthermore, the supCD28mAb treatment IL-10 and IL-4 showed significantly high concentrations on both day 3 and day 7, whereas the other kinds of on day 0 significantly inhibited the GvHD mortality in comparison to the recipients that received only the naive cytokines such as IL-6 and TNF-α showed no changes in rats (data not shown). These results suggest that the spleen cells. These findings were accompanied by an extensive perivascular infiltration of the mononuclear antibody action in humans and rats is different (19) .
In the present study, the systemic GvH reactivity of cells, and tissue damage was seen in the histological studies of the skin, tongue, lung, and liver from the na-the supCD28mAb treatment was tested by injecting an antibody via the tail veins of (Lewis × DA) F1 hybrid ive lymphocytes-transferred host on day 14 (7). In comparison, relatively few infiltrating mononuclear cells and recipients at various points. In agreement with our previous reports (2, 7, 8) , the rats that received the naive Lewis almost normal tissue architecture were observed in the supCD28mAb group (data not shown). On the other spleen lymphocytes experienced host weight loss and definite lethality (Table 1, Fig. 2 ). The supCD28mAb
hand, there were no protective effects in the supCD28 mAb-treated group on day 7 and day 10. These results treatment on day 3, before the T-cell transfer, did not indicate that supCD28mAb-treated early have potent im-in Figure 2 , the CD4 + CD25 + T cells increased and the Foxp3 + cells decreased in the antibody-treated non-munoregulatory activity on the response to allogeneic MHC antigens, even in a more sensitive assay. effective group (day 10). These data indicate that an analysis of the Foxp3 Tregs may be a helpful tool to Tregs specifically express the transcription factor Foxp3, which appears to act as a master control gene discriminate the severity and lethality of GvHD after allogeneic stem cell transplantation. for their development and function (3, 5, 6) . The forced expression of the Foxp3 gene can convert the murine Thirdly, we used a unique neonatal tolerant model, DA tolerant of (Lewis × DA) F1 rat, to determine naive T cells to nonnatural Tregs, which phenotypically and functionally resemble the natural Tregs (5) . Natural whether or not the activity of the supCD28mAbexpanded nTregs was antigen specific (Fig. 5A ). We Tregs also show homeostatic proliferation in a T-celldeficient environment, and a fraction of the cells can verified that the cells derived from the Lewis rat was present in the DA tolerant of (Lewis × DA) F1 rat, by proliferate in normal animals, presumably by recognizing the self-antigens (5) . These findings collectively in-using a specific antibody (clone I1-69) that recognized the Lewis MHC class I molecules (Fig. 5B ). After the dicate that Foxp3 is a master control gene for the development and function of natural Tregs.
antibody treatment, the majority of the expanded nTregs were DA derived. Similar to the (Lewis × DA) F1 host, Firstly, we showed that a progressive increase of the CD4 + CD25 + T-cell population on day 7 in the PB and the transfer of the naive Lewis lymphocytes to the DA tolerant of (Lewis × DA) F1 rat experienced host weight on day 3 in the spleen, after the transfer of naive Lewis lymphocytes, accompanied by a decrease of the Foxp3 + loss and definite lethality. However, there was no protective effect in the supCD28mAb-treated group on day cells in CD4 + CD25 + T-cell populations on day 7 in PB and on day 3 in spleen (Fig. 3B) . Secondly, the changes 3 in comparison to the same antibody treatment in the (Lewis × DA) F1 rat group, which did not mediate of the CD4 + CD25 + T cells and Foxp3 + Tregs populations in the host spleen and the PB after the supCD28mAb GvHD lethality in any recipients. Furthermore, we examined the antigen-specific nTregs activity by employ-treatment were investigated. The population of the CD4 + CD25 + T cells in the total lymphocyte was maintained ing autologous naive Lewis rat and allogeneic DA rat nTregs to test their suppressive activity by performing a at a fixed level, whereas the Foxp3 + cells dramatically increased in the CD4 + CD25 + T cells in the supCD28 mixed lymphocyte reaction assay. In agreement with the finding in the in vivo study (Figs. 2 and 5) , Lewis mAb treatment group on day 3. Consistent with the data Figure 4 . CD4 + CD25 + T-cell and Foxp3 + Treg populations in host spleen and PB on day 14 after supCD28mAb treatment. An FCM analysis showed an increase of the CD4 + CD25 + T-cell population on day 14 in spleen and PB after the transfer of naive Lewis lymphocytes, accompanied by a decrease of the Foxp3 + cells in the CD4 + CD25 + T-cell populations. The population of the CD4 + CD25 + T cells in total lymphocyte was maintained at a fixed level and Foxp3 + cells dramatically increased in CD4 + CD25 + T cells in the supCD28mAb treatment group on day 3. Similar to the no-treatment group, the CD4 + CD25 + T cells increased and the Foxp3 + cells decreased in the antibody-treated non effective group (day 10). nTregs inhibited the proliferation of naive Lewis supCD28mAb-expanded nTregs have potent antigenspecific immunoregulatory activity in response to the al-CD4 + CD25 − T cells stimulated with allogeneic DA rat APCs, whereas the nTregs from the DA rats had no ef-logeneic MHC antigens.
In conclusion, the current results confirm that fect on suppression of the Lewis CD4 + CD25 − T-cell proliferation. These results indicate that nTregs can sup-supCD28mAb can preferentially expand nTregs, which induced a potent inhibition of the lethality of GvHD via press the T-cell proliferation antigen specifically and the Systemic GvHD was performed transferring 2.5 × 10 8 naive Lewis T cells to DA tolerant of (Lewis × DA) F1 rats without x-ray. supCD28mAb (JJ316, 1 mg/rat) was administered to the host rat via tail veins at day 3 before T-cell infusion. The p-value was compared with control group rat and determined by the Kaplan-Meier test. 
